SynOx takes rare tumour treatment to phase 3 with $75m Series B from BioPharma-Reporter.com
The UK/Irish company SynOx Therapeutics plans to run a phase 3 trial of a potentially best-in-class antibody therapy for the rare disease Tenosynovial Giant Cell Tumour (TGCT) with the help of a $75 million financing round. The Series B round was led …